CStone Financial Statements From 2010 to 2025
| CSPHF Stock | USD 0.89 0.00 0.00% |
Check CStone Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CStone Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . CStone financial statements analysis is a perfect complement when working with CStone Pharmaceuticals Valuation or Volatility modules.
CStone |
CStone Pharmaceuticals Company Current Valuation Analysis
CStone Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current CStone Pharmaceuticals Current Valuation | 539.57 M |
Most of CStone Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CStone Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, CStone Pharmaceuticals has a Current Valuation of 539.57 M. This is 96.24% lower than that of the Healthcare sector and 88.38% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 96.75% higher than that of the company.
CStone Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining CStone Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare CStone Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CStone Pharmaceuticals competition to find correlations between indicators driving CStone Pharmaceuticals's intrinsic value. More Info.CStone Pharmaceuticals is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CStone Pharmaceuticals' earnings, one of the primary drivers of an investment's value.About CStone Pharmaceuticals Financial Statements
CStone Pharmaceuticals stakeholders use historical fundamental indicators, such as CStone Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although CStone Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in CStone Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on CStone Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in CStone Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. The company was incorporated in 2015 and is headquartered in Shanghai, China. Cstone Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 569 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in CStone Pink Sheet
CStone Pharmaceuticals financial ratios help investors to determine whether CStone Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CStone with respect to the benefits of owning CStone Pharmaceuticals security.